GSK 923295

Drug Profile

GSK 923295

Alternative Names: GSK-923295; GSK-923295A

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Cytokinetics
  • Developer GlaxoSmithKline
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Centromere protein E inhibitors; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 19 Nov 2009 Drug interactions data from a preclinical trial in Cancer presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
  • 19 Nov 2009 Pharmacodynamics data from in vitro studies in Solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009) ,
  • 01 Jun 2009 Pharmacodynamics data from a preclinical trial in Cancer presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top